The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma - Université de Reims Champagne-Ardenne Access content directly
Journal Articles Oncogene Year : 2019

The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma


Metastatic clear cell renal cell carcinoma (CCC) remains incurable despite advances in the development of anti-angiogenic targeted therapies and the emergence of immune checkpoint inhibitors. We have previously shown that the sonic hedgehog-Gli signaling pathway is oncogenic in CCC allowing us to identify the developmental Lim1 transcription factor as a Gli target and as a new oncogene in CCC regulating cell proliferation and apoptosis, and promoting tumor growth. In this previous study, preliminary in vitro results also suggested that Lim1 may be implicated in metastatic spread. Here we investigated the potential pro-metastatic role of Lim1 in advanced CCC (1) in vitro using a panel of CCC cell lines expressing or not the von Hippel-Lindau (VHL) tumor suppressor gene either naturally or by gene transfer and (2) ex vivo in 30 CCC metastatic tissues, including lymph nodes, lung, skin, bone, and adrenal metastases, and (3) in vivo, using a metastatic model by intravenous injection of siRNA-transfected cells into Balb/c nude. Our in vitro results reveal that Lim1 knockdown time-dependently decreased CCC cell motility, migration, invasion, and clonogenicity by up to 50% regardless of their VHL status. Investigating the molecular machinery involved in these processes, we identified a large panel of Lim1 targets known to be involved in cell adhesion (paxillin and fibronectin), epithelial-mesenchymal transition (Twist1/2 and snail), invasion (MMP1/2/3/8/9), and metastatic progression (CXCR4, SDF-1, and ANG-1). Importantly, Lim1 was found constitutively expressed in all metastatic tissues. The H-score in metastatic tissues being significantly superior to the score in the corresponding primary tumor tissues (P value = 0.009). Furthermore, we showed that Lim1 silencing decreases pulmonary metastasis development in terms of number and size in the in vivo metastatic model of human CCC. Taken together, these experiments strengthen the potential therapeutic value of Lim1 targeting as a promising novel approach for treating metastatic human CCC.
Fichier principal
Vignette du fichier
HamaidiImene_Oncogene_2019.pdf (993.17 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02431944 , version 1 (10-06-2020)



Imene Hamaidi, Catherine Coquard, Sabrina Danilin, Valérian Dormoy, Claire Béraud, et al.. The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma. Oncogene, 2019, 38 (1), pp.60-72. ⟨10.1038/s41388-018-0413-y⟩. ⟨hal-02431944⟩
78 View
341 Download



Gmail Facebook Twitter LinkedIn More